MorphoSys AG Announces Development of New Antibody Platform Technology

MARTINSRIED, Germany, Nov. 20, 2007 (PRIME NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR; Prime Standard Segment) today unveiled a multi-year technology development program which will lead to a significantly enhanced version of its antibody generation platform. The new system, which involves several technology components and maintains its modular construction, represents a technological breakthrough in the advancement of antibody library technology and will offer unequaled opportunities for antibody-based drug development. The new technology suite will include enhancements involving substantially faster and more direct access to high affinity antibody drug candidates in the full IgG format compared to other antibody technologies on the market.